AACR highlights an AACR26 session on emerging alternatives to animal toxicology and new FDA initiatives to reduce animal testing, signaling regulatory openness to new preclinical evidence methods.
While animal toxicology studies have been the primary method for assessing oncology products, alternative methods are emerging.
Haleh Saber will moderate an #AACR26 session highlighting new FDA initiatives to reduce animal testing.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare